Red blood cell-conjugated biomimetic nanomedicine for enhanced therapy of non-small cell lung cancer.

ABSTRACT: Rationale: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a standard therapy for non-small cell lung cancer (NSCLC). Despite their clinical efficacy, dose-limiting systemic toxicity and the eventual development of acquired resistance limit their long-term benefit. Therefore, innovative drug delivery strategies are highly demanded to optimize the therapeutic window, minimizing toxicity of EGFR-TKIs at lower doses without compromising their efficacy. Methods: We developed a red blood cell (RBC)-based biomimetic platform for the systemic delivery of EGFR-TKIs. Osimertinib-loaded poly(lactic-co-glycolic acid) nanoparticles were camouflaged with a biotinylated RBC membrane (Osi-RNPs). They were then conjugated to the surface of RBCs via high-aff

SUBMITTER: Chiang ST 

PROVIDER: S-EPMC12905782 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature